Personal wellness company WeightWatchers (NASDAQ: WW) met Wall Street’s revenue expectations in Q3 2026, but sales fell by 11.2% year on year to $152.9 million. On the other hand, the company’s full-year revenue guidance of $627.5 million at the midpoint came in 0.5% below analysts’ estimates. Its GAAP profit of $1.51 per share was significantly above analysts’ consensus estimates.

Is now the time to buy WW? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

WeightWatchers reported quarterly results in line with Wall Street’s consensus for revenue, but continued to face a challenging top line environment as overall sales declined year on year. Management pointed to the rapid growth in its Core+ and Med+ tiers, as well as a deliberate shift in marketing allocation, as key drivers supporting gross margin expansion and improved operating profitability. CEO Stephen Bye called out a “remarkable history” of member support and credited a holistic approach for driving increased engagement, particularly as the company adapts to a market shaped by new weight-loss medications and evolving consumer needs.

Looking forward, WeightWatchers’ guidance reflects a focus on growing its Med+ clinical offering and continued investment in behavioral support programs. Management emphasized the need to diversify marketing channels and better target both existing and new members, particularly seniors newly eligible for GLP-1 medications through the Medicare Bridge Program. CFO Felicia DellaFortuna noted that workflow automation and product development efficiencies are expected to help sustain gross margins, while CEO Stephen Bye stated, “We are well-positioned to achieve sustainable, profitable growth in 2027,” highlighting ongoing efforts to refine member experience and support across all tiers.

Key insights from management’s remarks

Management attributed margin gains to operational discipline and the rising share of higher-value subscription tiers, with Core+ and Med+ now representing about half of total revenue.

• Core+ tier momentum: The Core+ behavioral support tier recorded its fourth consecutive quarter of sequential subscriber growth, with a 16% increase year over year. Management credited both conversion from lower-price Core members and new signups, especially those participating in the GLP-1 Success Program, which more than doubled in engagement since January.
• Clinical revenue expansion: Clinical subscription revenue, primarily from Med+, grew 48% year over year, making up about 25% of total company revenue compared to 15% a year ago. This growth was driven by increased demand for GLP-1 medication support, as well as expanded access through programs like the Medicare Bridge initiative.
• Product portfolio shift: The shift toward higher-value offerings, including Med+ and Core+, has resulted in a higher average revenue per user (ARPU), with clinical ARPU reaching approximately $68—about five times greater than the Core tier. This change in mix contributed to overall operating margin improvement.
• Expense and marketing discipline: Operating margins benefited from strict cost control, including lower marketing and administrative expenses as a share of revenue. The company deliberately recalibrated marketing spend across offerings, focusing on product maturity and margin profile.
• Workflow automation: Improved workflow automation and more efficient service delivery supported gross margin gains, even as the clinical business—typically with higher service costs—became a larger portion of revenue. Management cited ongoing tech investments as central to maintaining these efficiencies.

Drivers of future performance

Management expects future performance to be shaped by expansion of the clinical offering, continued behavioral tier growth, and disciplined cost management amid a competitive GLP-1 landscape.

• Med+ and Medicare Bridge expansion: WeightWatchers is prioritizing awareness and adoption of Med+, particularly among seniors newly eligible for GLP-1 medication support via the Medicare Bridge Program. Management anticipates this could expand the addressable market and drive clinical revenue growth, though acknowledged that marketing execution will be key.
• Behavioral subscriber base stabilization: The company expects further gains in Core+ subscribers, with ongoing enhancements to digital tools and structured support programs such as menopause and GLP-1 Success. Management believes these offerings can help stabilize the behavioral subscriber base despite continued declines in the legacy Core tier.
• Margin sustainability risks: While workflow automation and expense management are expected to help maintain gross margins, management cautioned that clinical revenue carries higher costs. The company highlighted the need to balance growth in Med+ with ongoing operating discipline to avoid margin compression as product mix evolves.

Catalysts in upcoming quarters

Looking ahead, our analyst team will monitor (1) the pace of Med+ adoption, especially among seniors eligible through the Medicare Bridge Program, (2) stabilization or growth in Core+ behavioral subscribers amid ongoing product enhancements, and (3) margin trends as the mix shifts toward clinical revenue. Additional signposts will include updates on digital platform improvements and early outcomes from new distribution partnerships.

WeightWatchers currently trades at $12.14, in line with $12.14 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks that trumped tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.